Literature DB >> 26023560

Synchronous diffuse large B-cell lymphoma and malignant clonal plasma cells in bone marrow as primary presentation: a diagnostic and therapeutic challenge.

Ritesh Sachdev1, Shalini Goel2, Smeeta Gajendra3, Nitin Sood4.   

Abstract

Coexistence of Diffuse Large B-Cell Lymphoma (DLBCL) with other morphologically and phenotypically distinct lymphoid neoplasm although unusual, has been reported in literature. The most common lymphoid neoplasms associated with DLBCL are Hodgkin's lymphoma, mantle cell lymphoma and marginal zone lymphoma. However, they have been reported predominantly in the sites other than the bone marrow. Rarely, DLBCL associated with paraproteinemia of IgM type, result of monoclonal plasma cell proliferation, has also been reported in literature. There is either an associated increase in the free light chain levels or disruption in the normal kappa: lambda ratio. However, co-existence of DLBCL with malignant non secretory clonal plasma cells, diagnosed primarily in the bone marrow has not been reported in the literature.

Entities:  

Keywords:  Chemotherapy; Fibrosis; Hodgkin’s lymphoma

Year:  2015        PMID: 26023560      PMCID: PMC4437074          DOI: 10.7860/JCDR/2015/12362.5816

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  7 in total

1.  Composite mantle cell and diffuse large B-cell lymphoma: report of two cases.

Authors:  Albert K Ho; Carolin J Teman; Gregory P Smith; Daniel R Nightingale; Rodney R Miles
Journal:  Int J Surg Pathol       Date:  2011-10       Impact factor: 1.271

2.  The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement.

Authors:  Janine Campbell; John F Seymour; Jane Matthews; Max Wolf; Janey Stone; Surender Juneja
Journal:  Eur J Haematol       Date:  2006-03-09       Impact factor: 2.997

3.  Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index.

Authors:  Randy Chung; Raymond Lai; Peter Wei; Jason Lee; John Hanson; Andrew R Belch; A Robert Turner; Tony Reiman
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

Review 4.  Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge.

Authors:  Santiago Montes-Moreno; Carlos Montalbán; Miguel Angel Piris
Journal:  Leuk Lymphoma       Date:  2011-09-19

5.  Composite recurrent hodgkin lymphoma and diffuse large B-cell lymphoma: one clone, two faces.

Authors:  Qin Huang; Sharon P Wilczynski; Karen L Chang; Lawrence M Weiss
Journal:  Am J Clin Pathol       Date:  2006-08       Impact factor: 2.493

6.  Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities.

Authors:  Lluís Colomo; Florence Loong; Susana Rives; Stefania Pittaluga; Antonio Martínez; Armando López-Guillermo; Jesús Ojanguren; Vicens Romagosa; Elaine S Jaffe; Elías Campo
Journal:  Am J Surg Pathol       Date:  2004-06       Impact factor: 6.394

7.  Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component.

Authors:  M Christina Cox; Arianna Di Napoli; Stefania Scarpino; Gerardo Salerno; Caterina Tatarelli; Caterina Talerico; Mariangela Lombardi; Bruno Monarca; Sergio Amadori; Luigi Ruco
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.